Objective. To examine response to highly active antiretroviral therapy (HAART) among a sample of treatment-experienced patients in the late stage of human immunodeficiency virus (HIV) infection in residential health care facilities (RHCFs) in New York City facilities designated for HIV/AIDS (acquired immunodeficiency syndrome) when access and adherence are maximized.
INTRODUCTION

Standard therapeutic practice for human immunodeficiency virus (HIV) infection
has evolved from monotherapy to a combination regimen that includes two nucleoside analogues and a protease inhibitor or non-nucleoside reverse transcriptase inhibitor, referred to as highly active antiretroviral therapy (HAART). 1
This advance has lengthened survival significantly. 1' 2 The goal of this potent therapy is substantial and lasting suppression of HIV viral replication; the full benefit of these complex regimens depends on strict adherenced Access and adherence to HAART for certain disenfranchised persons, such as injection drug users (IDUs), the homeless, and mentally compromised patients, for whom coordinated medical services are often difficult to achieve, is of considerable public health concern. Physicians may be less likely to prescribe combination antiretroviral therapy to these patients because of concerns about nonadherence and subsequent viral resurgence or the development of viral resistance. 4 When issues of access and adherence are optimized, subsequent questions relate to the extent to which these therapies are tolerated and effective on a longterm basis. There is limited data on the response to HAART in a clinic setting in which medication access and adherence are maximized. In New York City, there is a constellation of residential health care facilities (RHCFs) with approximately 1,200 beds designated for HIV/AIDS acquired immunodeficiency syndrome. Originally established as hospice and terminal care centers, the advent of combination antiretroviral therapy has transformed these facilities to vital centers for supervised therapy for late-stage HIV-infected patients, the majority of whom are former or current drug users, and many have been homeless or in prison. The purpose of this preliminary report is to describe patients' demographic and clinical characteristics and to provide estimates of HAART response among late-stage HIV-infected IDUs and other marginalized patients when medication access and adherence have been maximized.
METHODS
STUDY SETTING AND PATIENT POPULATION
The AIDS residential health care facilities in New York City are not-for-profit, free-standing nursing facilities with revenue received primarily from public-based insurance/entitlements. These nursing facilities include traditional skilled nursing facilities and health-related facilities and provide a wide range of medical care, including AIDS specialist medical services, on-site methadone maintenance and other substance abuse treatment, subacute care, palliative care, skilled nursing care, speech, occupational and physical therapy, and HIV-prevention services.
Under the authority of the state legislature, the AIDS Institute of the New York State Department of Health has established clinical care guidelines and monitors HIV/AIDS care in these facilities.
To be eligible for admission to these facilities, a patient must meet the 1993 Centers for Disease Control definition for AIDS 5 and one of the eligibility categories on the patient review instrument. This is completed by the referring agency and relates to level of dependency and reimbursement. The overall demographics for the entire population based on 1997 aggregate data compiled by the New York State AIDS Institute are as follows: 55% African-American, 30% Hispanic; 58% male; median age 42 years. For patients in the facilities at any time during the fourth quarter of 1997, the average number of days in the facility (calculated from admission date to discharge date or end of 1997) was 15 months (mean 463 days, interquartile range 126 days-653 days). Drug use is the principal mode of HIV transmission for more than half of the patient population, and in some facilities is the leading HIV risk behavior for as much as 90% of the patient population. The average daily census is consistently above 85%.
To obtain more detailed data, in the fall of 1998 a standardized data abstraction form was designed to estimate clinical, immunologic, and virologic parameters in a sample of patients in the residential health care facilities. The study population represents a convenience sample from 6 of the 12 residential facilities in New York City and was drawn from residents who were in the facility for at least 3 months.
Demographic and medical history data abstracted from a standardized form completed for all patients at the time of admission to the facility included gender, 
STATISTICAL ANALYSIS
Frequency distributions were generated for the demographic, virologic, immunologic, and treatment variables. For the viral load results, data were log transformed (base 10), and results were dichotomized initially as >1/2 log decrease between admission and subsequent measurement as the cutoff for treatment success and in a separate analysis were dichotomized as >~ log increase as the cutoff for treatment nonresponse (to reflect that nearly all patients were initiated on combination therapy prior to admission). Using dichotomized outcomes of change in viral load measurements from two time points, cross tabulations with other variables were examined using chi-square or Fisher exact test for categorical data and t tests for continuous data.
RESULTS
Of 169 patients surveyed who had baseline CD4+ cell counts and RT-PCR HIV viral load results available in their charts for at least two time points, 34% (n = 58) did not have detectable viral load on admission for a final sample size of 111 for this analysis. The demographic characteristics of the 111 patients in this sample were similar to those of the overall RHCF patient population. Table I presents the descriptive demographic data of the sample. An overwhelming majority of 'the population were African-American or Hispanic (91%), with a mean age at admission of 42 years, 58% were males, and almost all (94%) were on Medicaid. Most of the patients were admitted from an acute care setting (48%), private home or apartment (21%), or correctional facility (14%); 39% were homeless prior to admission. The major HIV risk factor was drug use (57%), followed by heterosexual contact (26%); only 8% reported male same-sex contact. Mean age at admission 42 years.
For this preliminary report, we did not review medical records for daily adherence. of these patients reported a history of injection drug use. Of those who reported drug use, heroin use was the most common (77%), followed by cocaine use (68%).
Of those who reported drug use, 40% were on methadone, and 15% reported current illicit drug use (prior 6 months) (see Table II ).
The active AIDS-defining illnesses for which the patients were receiving treat- cytomegalovirus retinitis, Kaposi's sarcoma, esophageal candidiasis, cervical carcinoma, and HIV wasting. PCP was the most common AIDS-defining illness of those specified (16%), and 20% of the patients had two or more of the specified AIDS-defining conditions (Table II) . Other comorbidities included anemia, herpes simplex, mucosal candidiasis, human papillomavirus, HCV seropositivity, hepa-titis B surface antigenemia, and HIV-associated dementia. A notable percentage of the patients were coinfected with HCV (52%) or hepatitis B (22%); a substantial proportion of the IDUs (81%) were HCV seropositive. A substantial proportion had evidence of mental illness; 23% had a history of dementia at the time of admission, and 46% were on a psychotropic medication. Table III shows the percentage of patients on specific antiretroviral medications; 80% of the patients were on HAART. The most commonly prescribed protease inhibitor was nelfinavir (44%), and of those patients on at least one protease inhibitor, 22% were on two protease inhibitors. The majority of patients who were on ritonavir (80%) were also on another protease inhibitor. Other Expanded access protocols 10 levels cross tabulated by use of HAART; in the sample, the median time interval between admission and current viral load was 6 months. As Table IV For more detailed analysis of HAART therapy responsiveness based on increase versus no increase (to represent unresponsive versus responsive) in viral load among the 88 patients on HAART, we examined potential factors associated with viral load increase among these patients (Table IV) . Those with viral load increase were more likely than those with stable or decreased viral load to have a history of injection drug use (71% versus 64%), to be current (prior 6 months) IDUs (43% versus 36%), to be HCV seropositive (86% versus 53%, P = .10), and to have a positive PPD skin test (43% versus 30%), even though the initial CD4 § cell count, viral load levels, and duration of follow-up were similar. No further analysis was performed, given the small number of nonresponders in our sample.
DISCUSSION
In the present study, 52% of the patients receiving HAART experienced a greater than 1,4 log decrease in HIV viral load over an average period of 6 months. This is considerably less than results from the original clinical trails with nonnucleoside reverse transcriptase inhibitors and protease inhibitorsy ~ but is consistent with more recent longer term follow-up studies in clinical settings. 12 ' 14-16 Given that the patient population of the RHCFs is comprised of patients with late-stage HIV, they are likely to have been treated previously. Therefore, some benefit is likely to have been afforded, and stabilization of viral load (or maintenance of viral suppression) is a possible expected observation. Unfortunately, we did not have pharmacy records from the acute care setting prior to admission to our facilities and cannot describe this further. As these patients were treatmentexperienced on admission, we considered response or nonresponse to therapy on the basis of Increasing viral load inasmuch as therapy might be expected to produce a decrease, then stabilization, of viral load, but not an increase. Observing an increase in viral load in a proportion of patients (8%) receiving HAART, we further examined factors that might be associated with an increase in viral load.
Although adherence to therapy explains much of the magnitude and durability of therapeutic response, 3' s' 14-18 other factors in addition to adherence may have an impact on HAART. We might expect that those failing therapy (i.e., having a viral load increase) might be IDUs who are less adherent despite nursing supervision, or the failures possibly might be due to some interaction with the drugs of abuse. However, drug abuse itself was not associated significantly with viral load response. Among IDUs, the potential interaction of methadone and antiretroviral therapy, as well as the influence of hepatitis and chronic liver disease, is of additional concern.
In the present study, we also considered the effects of opiate substitution The stronger association of viral load increase with HCV seropositivity suggests that the sequelae of hepatitis may have importance for clinical management of patients on HAART. As we did not monitor liver function tests, it is also possible that hepatitis seropositivity may be a marker for other influential events.
These preliminary data suggest that, when access and adherence to HAART are maximized in IDUs, treatment response is similar to other clinic populations.
Despite the optimal treatment environment, 8% of the patients on HAART experienced treatment nonresponse (a greater than 89 log increase in viral load), and another 31% experienced no change in viral load or less than a 89 log decrease.
These data support the view that other factors in addition to adherence are likely to have an impact on HAART response. The RHCFs in New York City provide a unique opportunity to examine further factors associated with HAART response when medication access and adherence are maximized, particularly in populations with other contributory factors, such as chronic liver disease, treatment for drug abuse, and prior exposure to mono-or combination nucleoside analogues.
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